GM1 gangliosidosis (GM1) is an ultra-rare lysosomal storage disease caused by pathogenic variants in galactosidase beta 1 (GLB1; NM_000404) that result in a deficiency of lysosomal beta-galactosidase.1,2 Without sufficient enzyme activity, GM1 ganglioside and related glycoconjugates build to toxic levels, particularly in the central nervous system.3–5 The disease is primarily characterized by neurodegeneration, but systemic involvement is also present and varies across disease types and among individual patients, resulting in considerable phenotypic complexity. This evidence concerns the gene GLB1 and GM1 gangliosidosis.